

## **REGENXBIO** to Host Conference Call on May 7 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights

## April 30, 2019 11:00 AM EDT

ROCKVILLE, Md., April 30, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV<sup>®</sup> Technology Platform, today announced that it will host a conference call on Tuesday, May 7, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2019, and recent operational highlights.

To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 6379973. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at <u>www.regenxbio.com</u>. The recorded webcast will be available for approximately 30 days following the call.

## About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

## CONTACT:

Investors Heather Savelle, 212-600-1902

heather@argotpartners.com

Media David Rosen, 212-600-1902 david.rosen@argotpartners.com



C View original content:http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-7-to-discuss-first-quarter-2019-financial-results-and-recent-operational-highlights-300840244.html

SOURCE REGENXBIO Inc.